Drug Profile
Fluticasone furoate/levocabastine
Alternative Names: FF/levocabastine; Levocabastine/FF; Levocabastine/fluticasone furoateLatest Information Update: 08 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Androstadienes; Antiallergics; Antiasthmatics; Glucocorticoids; Piperidines; Sedating antihistamines; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 04 May 2016 No development reported - Phase-I for Allergic rhinitis (In volunteers) in Australia (Intranasal)
- 04 May 2016 No development reported - Phase-II for Allergic rhinitis in Austria (Intranasal)
- 28 Feb 2014 GlaxoSmithKline completes a phase I trial in Healthy volunteers in Australia (NCT01962467)